Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...
S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...
Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
It’s a situation Deanne Tingey is familiar with. Her daughter, Winter, caught RSV when she was just six weeks old and became severely ill and required hospitalisation. “Winter was struggling ...
Data from the Centers for Disease Control and Prevention showed an increase in three respiratory viruses—COVID-19, flu and RSV—and the gastrointestinal disease norovirus. Emergency department ...
Emergency department visits are "high" and "very high" for flu and RSV, respectively, and "elevated" for COVID-19 across the U.S., according to the CDC. As of the week ending Jan. 4, 18.6% of ...
Credit: seksan Mongkhonkhamsao via Getty Images. Shionogi has been awarded $375m by the US Department of Health and Human Services (HHS) to develop a long-acting therapeutic aimed at protecting ...
After seeing its Covid-19 drug fail in a Phase 3 trial last year, Shionogi on Thursday won a $375 million award from HHS to develop … ...
In the week ending Jan. 10, flu positivity testing was up 20% in California. The report shows moderate RSV activity and low COVID-19 activity in the same period. Norovirus, which causes sudden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback